Abstract
Severe acute respiratory syndrome (SARS-CoV-2) spread in whole of the world and was declared as pandemic by the WHO [world health organization]. SARS-CoV-2 has been responsible to cause more severe symptoms in immunocompromised patients. Much effort is currently being put into researching COVID-19's pathophysiology and treatment, although there are various parameters which are not very well known to us; reasons are still unknown. The purpose of the review is to encourage research into prognoses of COVID-19 infections in cancer patients, allowing for better clinical management of these patients. These researches will further help professionals to get the exact prognosis and help treat patients. These all features which will be mentioned in the article will show impact of covid on patients with various type of cancer. There are various risks associated with cancer during corona as these people are having very less immunity. Diseases which are very communicable easily infect people with cancer. There is no difference in symptoms seen in normal person and immunocompromised patients. The main motive is to help doctors in assessing prognosis and treatment.
Highlights
Severe acute respiratory syndrome (SARS-COV2) caused by novel coronavirus, has spread over the world, causing the COVID-19 pandemic [1]
Viral pneumonia is linked to 19% of deaths in immunocompromised patients, including does of cancer. This finding emphasises the need of assessing COVID-19 infection along with its treatment outcomes in cancer patients [4,5,6]
One study showed that previous associate degreeti-PD-1 medical care in carcinoma wasn't related to an hyperbolic chances of severity of COVID-19 [21]. what SARS-CoV-2 viral infection affects the fruitfulness and result of anti-cancer medical care rely upon our current understanding of organic chemistry and pathophysiological mechanism of COVID-19
Summary
Severe acute respiratory syndrome (SARS-COV2) caused by novel coronavirus, has spread over the world, causing the COVID-19 pandemic [1]. Incidence rates in cancer patients have increased as the pandemic has progressed, indicating a higher proportion of serious disease cases. Viral pneumonia is linked to 19% of deaths in immunocompromised patients, including does of cancer. This finding emphasises the need of assessing COVID-19 infection along with its treatment outcomes in cancer patients [4,5,6]. This is focused on clinical and molecular characteristics of corona infection in carcinoma patients in order to spur research for better managing COVID-19-infected cancer patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
